Trial Profile
A Phase III Randomized Study for HER2-Overexpressed Metastatic Breast Cancer Patients Treated by Trastuzumab (Cipterbin) Plus vinorelbinE Simultaneously or Sequencely.
Status:
Completed
Phase of Trial:
Phase IV
Latest Information Update: 08 Nov 2021
Price :
$35
*
At a glance
- Drugs Trastuzumab (Primary) ; Vinorelbine (Primary)
- Indications Advanced breast cancer
- Focus Registrational; Therapeutic Use
- Acronyms HOPES
- Sponsors Sunshine Guojian Pharmaceutical
- 14 Feb 2011 New trial record